Literature DB >> 31138602

AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.

David A Kircher1,2, Kirby A Trombetti1, Mark R Silvis1, Gennie L Parkman1,2, Grant M Fischer3, Stephanie N Angel1, Christopher M Stehn1, Sean C Strain1, Allie H Grossmann1,4,5, Keith L Duffy6, Kenneth M Boucher1,7, Martin McMahon1,2,6, Michael A Davies3, Michelle C Mendoza1,2, Matthew W VanBrocklin1,2,8, Sheri L Holmen9,2,8.   

Abstract

Alterations in the PI3K/AKT pathway occur in up to 70% of melanomas and are associated with disease progression. The three AKT paralogs are highly conserved but data suggest they have distinct functions. Activating mutations of AKT1 and AKT3 occur in human melanoma but their role in melanoma formation and metastasis remains unclear. Using an established melanoma mouse model, we evaluated E17K, E40K, and Q79K mutations in AKT1, AKT2, and AKT3 and show that mice harboring tumors expressing AKT1E17K had the highest incidence of brain metastasis and lowest mean survival. Tumors expressing AKT1E17K displayed elevated levels of focal adhesion factors and enhanced phosphorylation of focal adhesion kinase (FAK). AKT1E17K expression in melanoma cells increased invasion and this was reduced by pharmacologic inhibition of either AKT or FAK. These data suggest that the different AKT paralogs have distinct roles in melanoma brain metastasis and that AKT and FAK may be promising therapeutic targets. IMPLICATIONS: This study suggests that AKT1E17K promotes melanoma brain metastasis through activation of FAK and provides a rationale for the therapeutic targeting of AKT and/or FAK to reduce melanoma metastasis. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31138602      PMCID: PMC6726552          DOI: 10.1158/1541-7786.MCR-18-1372

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  55 in total

1.  Delivery of short hairpin RNA sequences by using a replication-competent avian retroviral vector.

Authors:  Jennifer L Bromberg-White; Craig P Webb; Veronique S Patacsil; Cindy K Miranti; Bart O Williams; Sheri L Holmen
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway.

Authors:  M Tamura; J Gu; E H Danen; T Takino; S Miyamoto; K M Yamada
Journal:  J Biol Chem       Date:  1999-07-16       Impact factor: 5.157

3.  AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.

Authors:  Jaclyn F Hechtman; Justyna Sadowska; Jason T Huse; Laetitia Borsu; Rona Yaeger; Jinru Shia; Efsevia Vakiani; Marc Ladanyi; Maria E Arcila
Journal:  Mol Cancer Res       Date:  2015-02-24       Impact factor: 5.852

4.  Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.

Authors:  Amanda D Bucheit; Guo Chen; Alan Siroy; Michael Tetzlaff; Russell Broaddus; Denai Milton; Patricia Fox; Roland Bassett; Patrick Hwu; Jeffrey E Gershenwald; Alexander J Lazar; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-08-27       Impact factor: 12.531

5.  A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Authors:  Hubing Shi; Aayoung Hong; Xiangju Kong; Richard C Koya; Chunying Song; Gatien Moriceau; Willy Hugo; Clarissa C Yu; Charles Ng; Thinle Chodon; Richard A Scolyer; Richard F Kefford; Antoni Ribas; Georgina V Long; Roger S Lo
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

6.  AKT1 Activation Promotes Development of Melanoma Metastases.

Authors:  Joseph H Cho; James P Robinson; Rowan A Arave; William J Burnett; David A Kircher; Guo Chen; Michael A Davies; Allie H Grossmann; Matthew W VanBrocklin; Martin McMahon; Sheri L Holmen
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

7.  Dynamin participates in focal extracellular matrix degradation by invasive cells.

Authors:  Massimiliano Baldassarre; Arsenio Pompeo; Galina Beznoussenko; Claudia Castaldi; Salvatore Cortellino; Mark A McNiven; Alberto Luini; Roberto Buccione
Journal:  Mol Biol Cell       Date:  2003-03       Impact factor: 4.138

8.  Therapeutic Implications of Targeting AKT Signaling in Melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Enzyme Res       Date:  2011-03-23

9.  Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.

Authors:  Eishu Hirata; Maria Romina Girotti; Amaya Viros; Steven Hooper; Bradley Spencer-Dene; Michiyuki Matsuda; James Larkin; Richard Marais; Erik Sahai
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

10.  Survival rates of patients with metastatic malignant melanoma.

Authors:  A Sandru; S Voinea; E Panaitescu; A Blidaru
Journal:  J Med Life       Date:  2014 Oct-Dec
View more
  15 in total

Review 1.  The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance.

Authors:  Gennie L Parkman; Mona Foth; David A Kircher; Sheri L Holmen; Martin McMahon
Journal:  Exp Dermatol       Date:  2021-11-09       Impact factor: 3.960

2.  AMBRA1 and FAK1: crosstalking for improved targeted therapy in melanoma.

Authors:  Luca Di Leo; Daniela De Zio
Journal:  Mol Cell Oncol       Date:  2021-07-13

3.  An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study.

Authors:  Teresa Amaral; Heike Niessner; Tobias Sinnberg; Ioannis Thomas; Andreas Meiwes; Claus Garbe; Marlene Garzarolli; Ricarda Rauschenberg; Thomas Eigentler; Friedegund Meier
Journal:  Neurooncol Adv       Date:  2020-10-22

4.  Model-dependent outcomes: Sex as a biological variable in preclinical mouse models of melanoma.

Authors:  Gennie L Parkman; David A Kircher; Christopher M Stehn; Martin McMahon; Sheri L Holmen
Journal:  Pigment Cell Melanoma Res       Date:  2020-11-11       Impact factor: 4.693

5.  Loss of Ambra1 promotes melanoma growth and invasion.

Authors:  Luca Di Leo; Valérie Bodemeyer; Francesca M Bosisio; Giuseppina Claps; Marco Carretta; Salvatore Rizza; Fiorella Faienza; Alex Frias; Shawez Khan; Matteo Bordi; Maria P Pacheco; Julie Di Martino; Jose J Bravo-Cordero; Colin J Daniel; Rosalie C Sears; Marco Donia; Daniel H Madsen; Per Guldberg; Giuseppe Filomeni; Thomas Sauter; Caroline Robert; Daniela De Zio; Francesco Cecconi
Journal:  Nat Commun       Date:  2021-05-05       Impact factor: 14.919

6.  AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.

Authors:  Sizhi Paul Gao; Amber J Kiliti; Kai Zhang; Naresh Vasani; Ninghui Mao; Emmet Jordan; Hannah C Wise; Tripti Shrestha Bhattarai; Wenhuo Hu; Madeline Dorso; James A Rodrigues; Kwanghee Kim; Aphrothiti J Hanrahan; Pedram Razavi; Brett Carver; Sarat Chandarlapaty; Jorge S Reis-Filho; Barry S Taylor; David B Solit
Journal:  Mol Cancer Res       Date:  2020-12-10       Impact factor: 6.333

7.  A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours.

Authors:  Claire L Adams; Emanuela Ercolano; Sara Ferluga; Agbolahan Sofela; Foram Dave; Caterina Negroni; Kathreena M Kurian; David A Hilton; C Oliver Hanemann
Journal:  Int J Mol Sci       Date:  2020-02-13       Impact factor: 5.923

Review 8.  Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.

Authors:  Manuel Valiente; Amanda E D Van Swearingen; Carey K Anders; Amos Bairoch; Adrienne Boire; Paula D Bos; Diana M Cittelly; Neta Erez; Gino B Ferraro; Dai Fukumura; Brunilde Gril; Meenhard Herlyn; Sheri L Holmen; Rakesh K Jain; Johanna A Joyce; Mihaela Lorger; Joan Massague; Josh Neman; Nicola R Sibson; Patricia S Steeg; Frits Thorsen; Leonie S Young; Damir Varešlija; Adina Vultur; Frances Weis-Garcia; Frank Winkler
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

9.  Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics.

Authors:  Weikai Xiao; Guochun Zhang; Bo Chen; Xiaoqing Chen; Lingzhu Wen; Jianguo Lai; Xuerui Li; Min Li; Hao Liu; Jing Liu; Han Han-Zhang; Analyn Lizaso; Ning Liao
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

Review 10.  Mouse models of uveal melanoma: Strengths, weaknesses, and future directions.

Authors:  Jackson R Richards; Jae Hyuk Yoo; Donghan Shin; Shannon J Odelberg
Journal:  Pigment Cell Melanoma Res       Date:  2020-01-22       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.